Compare Amcor PLC (AMCR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amcor PLC vs Johnson & Johnson — how do they compare? Amcor PLC trades at $43 (market cap $19.96B), while Johnson & Johnson trades at $258.35 (market cap $618.61B). The key difference: Johnson & Johnson is far larger — about 31× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| AMCR | JNJ | |
|---|---|---|
Market Cap | $19.96B | $618.61B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $267.24 |
52-Week Low | $36.69 | $155.17 |
Enterprise Value | $35.08B | $651.54B |
Dividend Yield | 6.02% | 2.09% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
Johnson & Johnson (JNJ) trades at $256.98, down 0.82% today, with a bullish technical signal from moving averages and a consensus analyst price target of $268.50. The company reported strong Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a net income margin of 21.83%. Recent news highlights dividend growth strategies and comparisons with peers like AbbVie, while cash flow trends show operational strength despite negative net cash flow in 2025.
JNJ presents a stable investment opportunity with consistent earnings beats and a solid dividend, but faces risks from rising debt levels and competitive pressures. The stock's current valuation metrics, including a P/E of 29.78, suggest it is fairly valued with moderate upside potential based on analyst targets. Investors should weigh the company's strong fundamentals against macroeconomic and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
